About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 13590 record(s)
Req # A-2020-000326
Adverse Reaction Reports (AERs) for Mezavant. Report numbers: E2B_02825035, E2B_02882429, E2B_02907794, E2B_02913170, E2B_02913375, E2B_02973212, E2B_02959658, E2B_02955630, E2B_02955280, E2B_02944188, E2B_02933965, E2B_02931008, E2B_02925932.Organization: Health Canada
March 2021
Req # A-2020-000364
Adverse Drug Reaction (ADR) for TERIFLUNOMIDE. Report number: E2B_02791526.Organization: Health Canada
March 2021
Req # A-2020-000592
Adverse Drug Reaction (ADR) for Botulinum toxin type A. Report number: E2B_03136030.Organization: Health Canada
March 2021
Req # A-2020-000889
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-110509-318, Laboratories Canada Overview.Organization: Health Canada
March 2021
Req # A-2020-000993
Adverse Reaction Reports (AERs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_01354481, E2B_02405078.Organization: Health Canada
March 2021
Req # A-2020-001075
Adverse Reaction Reports (AERs). Report numbers: E2B_03257835, E2B_03257836, E2B_03259803.Organization: Health Canada
March 2021
Req # A-2020-001329
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-113071-262, Procedures for Addressing Allegations of Breach of Scientific Integrity.Organization: Health Canada
March 2021
Req # A-2020-001371
Adverse Reaction Reports (AERs) for LEUPROLIDE ACETATE. Report numbers: E2B_03023786, E2B_03023776.Organization: Health Canada
March 2021
Req # A-2020-001554
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-075533-873, Meeting with Social Sciences and Humanities Research Council.Organization: Health Canada
March 2021
Req # A-2020-001597
Adverse Drug Reaction (ADR). Report number: E2B_03352370.Organization: Health Canada
March 2021